<article>US-based healthcare fund management firm <a style="color: #000080;" href="https://www.dealstreetasia.com/?s=OrbiMed" target="_blank" rel="noopener noreferrer">OrbiMed</a> led a $30 million Series C preferred equity financing round in <a style="color: #000080;" href="https://www.dealstreetasia.com/?s=zai+lab" target="_blank" rel="noopener noreferrer">Zai Lab Ltd</a>, a bio-pharmaceutical company in Shanghai, China.</article>

US-based healthcare fund management firm <a style="color: #000080;" href="https://www.dealstreetasia.com/?s=OrbiMed" target="_blank" rel="noopener noreferrer">OrbiMed</a> led a $30 million Series C preferred equity financing round in <a style="color: #000080;" href="https://www.dealstreetasia.com/?s=zai+lab" target="_blank" rel="noopener noreferrer">Zai Lab Ltd</a>, a bio-pharmaceutical company in Shanghai, China.
New investors <a style="color: #000080;" href="https://www.dealstreetasia.com/?s=vivo+capital" target="_blank" rel="noopener noreferrer">Vivo Capital</a>, <a style="color: #000080;" href="https://www.dealstreetasia.com/?s=Cormorant" target="_blank" rel="noopener noreferrer">Cormorant</a> and <a style="color: #000080;" href="https://www.dealstreetasia.com/?s=Rock+Springs+Capital" target="_blank" rel="noopener noreferrer">Rock Springs Capital</a> also joined the round.
JP Morgan served as placement agent to Zai Lab on the Series C financing.
Founded in 2013, Zai Lab is focused on discovering or licensing, developing and commercialising proprietary therapeutics that address areas such as oncology, autoimmune and infectious diseases.
&#8220;Proceeds from the fund-raising will go toward Zai Lab&#8217;s research and development efforts and also support future partnering activities,&#8221; the bio-pharma company said in its statement.
OrbiMed manages $13 billion across public and private company investments worldwide. It currently has a team of over 80 scientific, medical, investment and other professionals. Investments by OrbiMed are made in one of three strategies &#8212; public equity, private equity, and royalty opportunities.
Also Read: 
<a style="color: #ff0000;" href="https://www.dealstreetasia.com/stories/biotech-startup-inventisbio-raises-19m-led-orbimed-asia-73863/" target="_blank" rel="noopener noreferrer">Orbimed Asia leads $19m round in Chinese biotech startup InventisBio</a>
<a style="color: #ff0000;" href="https://www.dealstreetasia.com/stories/netmeds-com-raises-50m-funding-led-by-us-based-orbimed-16978/" target="_blank" rel="noopener noreferrer">India: Netmeds.com raises $50m funding led by US-based OrbiMed</a>
<a style="color: #ff0000;" href="https://www.dealstreetasia.com/stories/24577-24577/" target="_blank" rel="noopener noreferrer">Healthcare-focused OrbiMed closes sixth VC fund at $950m</a>
<a style="color: #ff0000;" href="https://www.dealstreetasia.com/stories/vivo-capital-leads-100m-funding-in-sino-healthcare-vc-fund-42292/" target="_blank" rel="noopener noreferrer">Vivo Capital raises $100m for new Sino-healthcare VC fund</a>

OrbiMed led a $30 million Series C preferred equity financing round in Zai Lab Ltd, a bio-pharmaceutical company in Shanghai, China.

China: OrbiMed leads $30m Series C in biopharma firm Zai Lab

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

China: OrbiMed leads $30m Series C in biopharma firm Zai Lab

Start your deal-making journey now!

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief